Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
A profound comprehension of the physiological function of intestinal homeostasis and permeability is essential to more accurately evaluate the prospective application of GLP-1 RAs in patients with ongoing inflammation
Basically, it mimics and boosts those signals
But it does sharpen what the relevant question is
US$ 27.05
US$ 29.46
US$ 26.67
US$ 25.71
US$ 29.44
US$ 22.59
US$ 27.21
